IDYA (IDEAYA Biosciences) Institutional Ownership: 114.02% (As of Jul. 05, 2026)


IDYA IDEAYA Biosciences Inc IDYA
54 GF Score
Price $37.66
GF Value $205.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Institutional Ownership?

IDEAYA Biosciences IDYA +4.12% 54 Institutional Ownership is 114.02% as of Jul. 05, 2026. GuruFocus rates IDYA with a GF Score™ of 54/100 and a GF Value™ of $205.30 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, IDEAYA Biosciences's institutional ownership is 114.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, IDEAYA Biosciences's Insider Ownership is 1.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, IDEAYA Biosciences's Float Percentage Of Total Shares Outstanding is 86.07%.

IDEAYA Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for IDEAYA Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEAYA Biosciences Institutional Ownership Chart

IDEAYA Biosciences Historical Data

The historical data trend for IDEAYA Biosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 74.81 75.34 75.98 73.97 73.64 75.12 72.18 72.13 72.18 73.13
IDYA
54GF Score
IDEAYA Biosciences Inc IDYA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEAYA Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 114.02% mean?
IDEAYA Biosciences (IDYA) has a Institutional Ownership of 114.02% as of Jul. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IDEAYA Biosciences and its competitors.
Is IDEAYA Biosciences' Institutional Ownership too high?
IDEAYA Biosciences' current Institutional Ownership is 114.02%. Overall, IDEAYA Biosciences has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Institutional Ownership compare to PBLS and ELVN?
IDEAYA Biosciences' Institutional Ownership of 114.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current Institutional Ownership is 114.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $205.30, compared to a current price of $37.66 — trading 81.7% below its estimated fair value. The current Institutional Ownership is 114.02%. IDEAYA Biosciences' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Institutional Ownership is 114.02% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $37.66 is trading 81.7% below its estimated GF Value™ of $205.30. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • Institutional Ownership: 114.02%
  • GF Value™: $205.30 vs. price of $37.66 (81.7% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
54GF Score

Get the complete analysis for IDYA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.66
Price
$205.30
GF Value